Chronic inflammation leaves long-lasting impression on gut stem cells, increasing colorectal cancer risk

A groundbreaking NIH-funded animal study, published today, Wednesday, March 25, 2026, reveals a critical molecular mechanism that explains how chronic inflammation in the gut can significantly elevate the risk of developing colorectal cancer. Researchers, simulating chronic colitis in mice, observed that the enduring impact of inflammation left a "heritable memory" within gut stem cells, which persisted for months after the inflammatory condition had subsided. This cellular memory was found to increase the activity of a specific group of proteins, AP-1 transcription factors, ultimately promoting accelerated tumor growth. The findings offer a pivotal understanding of the complex interplay between inflammation and oncogenesis, potentially paving the way for novel diagnostic and therapeutic strategies.

Unraveling the Molecular Link

The connection between chronic inflammation and various forms of cancer has long been recognized by the scientific community, but the precise molecular pathways underlying this association have largely remained elusive. This new research sheds considerable light on these mechanisms, providing a detailed account of how repeated cycles of injury and repair in the gut can predispose an individual to colorectal cancer. Dr. Anthony Letai, M.D., Ph.D., director of NIH’s National Cancer Institute (NCI), underscored the significance of the discovery, stating, "By spelling out how repeated cycles of injury in the gut may influence colorectal cancer risk, the authors have potentially opened avenues toward much-needed methods of early evaluation and therapy for a condition that is of increasing concern." This statement highlights the potential for these findings to revolutionize the approach to a disease that continues to pose a major global health challenge.

The Persistent Legacy of Inflammation: Epigenetic Memory

The study, primarily conducted by researchers at the Broad Institute of MIT and Harvard, meticulously analyzed animals and organoids derived from their injured tissue. A key finding was the observation that cellular damage instigated by inflammation resulted in profound alterations in stem cells. Crucially, these alterations were inherited by new cells for more than 100 days even after the cessation of colitis. This phenomenon is distinct from changes to an individual’s DNA, which generally remains stable over time. Instead, the researchers focused on the epigenome—the dynamic collection of chemical annotations to the genome that influences gene expression without altering the underlying DNA sequence.

Epigenetic flexibility is a vital cellular mechanism, enabling cells to adapt to fluctuating circumstances, such as the stress caused by damaging inflammation. This adaptation typically involves modulating the expression of specific genes, including those involved in regeneration and repair. While these adaptations are initially beneficial, acting as a form of cellular memory, recent research, including this study, indicates that they can have unintended, detrimental long-term consequences, inadvertently increasing the risk of cancer. The persistence of these "memories" suggests a fundamental shift in cellular identity that outlasts the initial inflammatory insult, creating a fertile ground for cancerous transformation.

Methodology: Tracking Cellular Changes

To arrive at these conclusions, the research team undertook an extensive investigation, examining over 52,000 individual cells across the animal models. This detailed single-cell analysis allowed them to pinpoint a specific epigenetic change that was particularly prominent. The results indicated that colitis triggered an alteration in colonic stem cells that significantly boosted the activity of AP-1 transcription factors. These transcription factors are well-known for their role in steering cellular responses to various forms of stress, including inflammation and injury. The epigenetic memory of this heightened AP-1 activity was remarkably durable, persisting in the epigenomes of cells for over three months after the colitis-inducing chemicals were withdrawn from the animals.

To further elucidate the longevity and transmissibility of this alteration, the researchers developed an innovative method to track epigenetic memories as cells divided within an organoid model of colitis. These organoids, essentially miniature organs grown in a lab dish from injured mouse tissue, provided a controlled environment to observe cellular behavior. Through this sophisticated approach, the team confirmed that the memory of elevated AP-1 activity was indeed heritable, with colonic stem cells faithfully passing this epigenetic blueprint down to new daughter cells as they proliferated. This confirmed the cellular "memory" aspect, demonstrating its capacity to be perpetuated across generations of cells.

AP-1 Transcription Factors: A Central Player

Having established the persistence and heritability of the epigenetic memory, the next critical step for the researchers was to ascertain whether this enduring effect of chronic inflammation truly had implications for cancer risk. To achieve this, they introduced genes known to spark tumor growth into two groups of mice: one group that had previously recovered from chronic colitis and another group that had always been healthy. The stark findings revealed a significantly accelerated rate of colorectal tumor growth in the colitis-recovered animals compared to the control group. This direct link solidified the hypothesis that chronic inflammation leaves a lingering mark that actively promotes cancer development.

Dr. Jason Buenrostro, Ph.D., corresponding author of the study and a distinguished member of the Broad Institute and professor at Harvard University, commented on this crucial finding: "We have known for some time that colitis can accelerate tumor growth after cancer has already begun, but here we show that the effect of chronic inflammation on cancer risk remains well after animals have recuperated." His statement underscores the novelty of demonstrating a pre-cancerous impact of inflammation that persists long after the acute phase has passed.

Further investigation by the team identified that a multitude of regenerative activities associated with AP-1 were in overdrive within the tumors of the recovered animals. This overactivity indicated that the epigenetic memory was not just a passive marker but an active driver of tumor progression. Crucially, when the researchers specifically blocked AP-1 activity, the pro-cancer effect induced by colitis disappeared. This intervention provided compelling evidence that AP-1 transcription factors are indeed a central molecular player, serving as a critical link between chronic gut inflammation and the increased risk of colorectal cancer.

The Broader Context: Colorectal Cancer and Inflammatory Bowel Disease

Colorectal cancer (CRC) remains a formidable public health challenge globally. According to the World Health Organization, it is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. In the United States, the American Cancer Society estimates that there will be approximately 106,590 new cases of colon cancer and 46,220 new cases of rectal cancer in 2023 alone. A particularly concerning trend is the rising incidence of early-onset CRC among individuals under 50, a demographic traditionally considered low-risk. This increase has spurred intensified research into novel risk factors and preventative strategies.

A well-established risk factor for CRC is inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn’s disease. IBD affects millions globally, characterized by chronic inflammation of the digestive tract. Patients with IBD have a significantly elevated lifetime risk of developing CRC, with the risk increasing with the duration, extent, and severity of the inflammation. For instance, individuals with extensive ulcerative colitis for over 8-10 years may face a cumulative CRC risk of up to 30% or more over 30 years. However, the precise mechanisms by which this chronic inflammation transitions into cancer have not been fully understood, making the current study’s findings particularly impactful. This research provides a tangible molecular explanation for this long-observed clinical correlation, bridging a critical gap in our understanding.

Implications for Colorectal Cancer Risk and Treatment

The profound insights generated by this study carry significant implications for the future of colorectal cancer diagnosis and therapy. Buenrostro and his colleagues express optimism that if this epigenetic phenomenon manifests similarly in humans, it could lead to the development of novel diagnostic tests capable of identifying individuals at high risk for colorectal cancer much earlier. Current screening methods for CRC, such as colonoscopy, sigmoidoscopy, and stool-based tests, are effective but often applied broadly or only to symptomatic individuals. An epigenetic marker could allow for a more personalized risk assessment, particularly beneficial for individuals with a history of IBD or other chronic inflammatory conditions, enabling targeted surveillance and preventative interventions.

Moreover, the identification of AP-1 transcription factors as a central player opens up promising new avenues for therapeutic development. The study’s success in reversing the pro-cancer effect by blocking AP-1 activity in mice suggests that future therapeutics could be designed to disrupt this post-colitis AP-1 activity in humans. Such drugs could potentially stall tumor growth or even prevent its initiation in high-risk patients. This represents a significant shift from treating established cancers to proactively intervening at an earlier, pre-malignant stage, offering the potential for improved patient outcomes and reduced mortality rates associated with CRC.

Towards Early Detection and Novel Therapies

The development of non-invasive or minimally invasive tests to detect these epigenetic memories would be a major leap forward. Imagine a blood or stool test that could identify these specific epigenetic signatures in individuals who have experienced chronic gut inflammation, long before any cancerous lesions form. This could lead to a more nuanced approach to screening, allowing clinicians to stratify risk more effectively and recommend more frequent or intensive surveillance for those with the persistent epigenetic "memory."

On the therapeutic front, drug discovery efforts could focus on molecules that specifically modulate AP-1 activity or downstream pathways that are aberrantly activated. This precision medicine approach could offer targeted interventions with potentially fewer side effects compared to broad-spectrum chemotherapy. Furthermore, understanding the epigenetic mechanisms involved could inform dietary or lifestyle interventions, as epigenetic marks are known to be influenced by environmental factors. For instance, research into specific nutrients or compounds that can modify AP-1 activity or reverse inflammatory epigenetic marks could become a new frontier in cancer prevention.

A Collaborative Scientific Endeavor

This comprehensive study is part of the Cancer Grand Challenges team PROSPECT, an international collaborative initiative dedicated to tackling some of the toughest challenges in cancer research. The project receives substantial support from a consortium of prestigious funding bodies, including NCI grants 1OT2CA297577 and 3OT2CA297577, Cancer Research UK, the French National Cancer Institute, and the Bowelbabe Fund for Cancer Research UK. Additional funding was provided by the National Human Genome Research Institute (NHGRI) through grant UM1HG011986 and by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through grant P30DK034854. This multi-institutional and international funding underscores the significance and collaborative nature of modern scientific breakthroughs, pooling resources and expertise to address complex health issues.

Looking Ahead: The Future of Precision Oncology

The findings from this NIH-funded research represent a critical step forward in understanding the intricate relationship between inflammation and cancer. By uncovering the enduring epigenetic "memory" left by chronic gut inflammation and pinpointing the role of AP-1 transcription factors, scientists have provided a concrete molecular explanation for a long-observed clinical phenomenon. This breakthrough offers a tangible roadmap for developing new strategies for early detection and targeted therapies for colorectal cancer, especially for individuals at heightened risk due to inflammatory conditions. As research continues to delve deeper into the epigenome and its role in disease, the promise of precision oncology—tailoring prevention and treatment based on an individual’s unique molecular profile—moves ever closer to becoming a clinical reality.